Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 1, 2011, Pages 155-161

  Chen, Kuen Feng ^a   Chen, Hui Ling ^a   Tai, Wei Tien ^a,b   Feng, Wen Chi ^a   Hsu, Chih Hung ^a   Chen, Pei Jer ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H)ONE; MK 2206; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P85; SORAFENIB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84984541581     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175786     Document Type: Article

References (29)

1. Adnane L, Trail PA, Taylor I, and Wilhelm SM (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612. (Pubitemid 43815979)
2. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, Trillaud H, et al. (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 50:481-489.
3. Bruix J and Llovet JM (2003) HCC surveillance: who is the target population? Hepatology 37:507-509.
4. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, and Cheng AL (2009) Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284:11121-11133.
5. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, and Cheng AL (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68:6698-6707.
6. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, and Cheng AL (2010) Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52:88-95.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34.
8. Di Maio M, Daniele B, and Perrone F (2009) Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol 6:505-506.
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134. (Pubitemid 46089673)
10. Fransvea E, Paradiso A, Antonaci S, and Giannelli G (2009) HCC heterogeneity: molecular pathogenesis and clinical implications. Cell Oncol 31:227-233.
11. Gills JJ and Dennis PA (2009) Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11:102-110.
12. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967.
13. Huo TI, Wu JC, and Lee SD (2005) Comparison of staging systems for HCC: one more positive answer or mission impossible? Hepatology 42:238-239.
14. Huynh H (2010) Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs 15:13-26.
15. Johnson P and Billingham L (2009) Sorafenib for liver cancer: the horizon broadens. Lancet Oncol 10:4-5.
16. Lindsley CW (2010) The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 10:458-477.
17. Lindsley CW, Barnett SF, Layton ME, and Bilodeau MT (2008) The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 8:7-18. (Pubitemid 351237905)
18. Liu P, Cheng H, Roberts TM, and Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
20. Midorikawa Y, Sugiyama Y, and Aburatani H (2010) Molecular targets for liver cancer therapy: from screening of target genes to clinical trials. Hepatol Res 40:49-60.
21. Palmer DH (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:2498-2499.
22. Panka DJ, Wang W, Atkins MB, and Mier JW (2006) The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66:1611-1619. (Pubitemid 43259945)
23. Scanga A and Kowdley K (2009) Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? Hepatology 49:332-334.
24. Thomas M (2009) Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 44 (Suppl 19):136-141.
25. Villanueva A, Minguez B, Forner A, Reig M, and Llovet JM (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61:317-328.
26. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, and Cillo U (2010) Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51:165-173.
27. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, and Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835-844. (Pubitemid 44480537)
28. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109. (Pubitemid 39331023)
29. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás- Cardama A, Small D, Cortes J, et al. (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100:184-198. (Pubitemid 351480557)